

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): January 24, 2018**

**Dextera Surgical Inc.**

(Exact Name of Registrant as Specified in its Charter)

**Delaware**  
(State or Other Jurisdiction  
of Incorporation)

**000-51772**  
(Commission  
File Number)

**94-3287832**  
(IRS Employer  
Identification No.)

**900 Saginaw Drive, Redwood City, CA**  
(Address of Principal Executive Offices)

**94063**  
(Zip Code)

Registrant's telephone number, including area code: (650) 364-9975

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

---

**Item 1.03. Bankruptcy or Receivership.**

As previously disclosed, on December 11, 2017, Dexter Surgical Inc. and Aesculap, Inc. (or its designee, “*Aesculap*”) entered into an Asset Purchase Agreement (the “*Asset Purchase Agreement*”) pursuant to which Dexter Surgical agreed to sell substantially all of its assets to Aesculap for \$17.3 million. Immediately thereafter, Dexter Surgical filed a voluntary petition for reorganization under Chapter 11 of Title 11 of the United States Code in the United States Bankruptcy Court for the District of Delaware (the “*Court*”).

Consistent with the terms of the Asset Purchase Agreement, on January 5, 2018, the Court approved bidding procedures and established January 19, 2018, as the deadline for the submission of any topping bids for Dexter Surgical’s assets and set January 22, 2018, as the date for an auction for the sale of the assets, if one or more topping bids were submitted. No other bids to purchase Dexter Surgical’s assets were submitted by the bid deadline and, as a result, the auction was cancelled. At a hearing held on January 24, 2018, the Court entered an order approving the sale of substantially all of Dexter Surgical’s assets to Aesculap pursuant to the Asset Purchase Agreement.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dexter Surgical Inc.

Date: January 25, 2018

/s/ Robert Y. Newell  
Robert Y. Newell  
Chief Financial Officer